UGT1AandUGT2BGenetic Variation Alters Nicotine and Nitrosamine Glucuronidation in European and African American Smokers
Open Access
- 1 January 2015
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 24 (1) , 94-104
Abstract
Background: Identifying sources of variation in the nicotine and nitrosamine metabolic inactivation pathways is important to understanding the relationship between smoking and cancer risk. Numerous UGT1A and UGT2B enzymes are implicated in nicotine and nitrosamine metabolism in vitro; however, little is known about their roles in vivo. Methods: Within UGT1A1, UGT1A4, UGT1A9, UGT2B7, UGT2B10, and UGT2B17, 47 variants were genotyped, including UGT2B10*2 and UGT2B17*2. The association between variation in these UGTs and glucuronidation activity within European and African American current smokers (n = 128), quantified as urinary ratios of the glucuronide over unconjugated compound for nicotine, cotinine, trans-3′-hydroxycotinine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), was investigated in regression models assuming a dominant effect of variant alleles. Results: Correcting for multiple testing, three UGT2B10 variants were associated with cotinine glucuronidation, rs2331559 and rs11726322 in European Americans and rs835309 in African Americans (P ≤ 0.0002). Additional variants predominantly in UGT2B10 were nominally associated with nicotine (P = 0.008–0.04) and cotinine (P = UGT2B10*2 in European Americans (P = 0.01, P < 0.001). UGT2B17*2 (P = 0.03) in European Americans and UGT2B7 variants (P = 0.02–0.04) in African Americans were nominally associated with 3HC glucuronidation. UGT1A (P = 0.007–0.01), UGT2B10 (P = 0.02), and UGT2B7 (P = 0.02–0.03) variants in African Americans were nominally associated with NNAL glucuronidation. Conclusions: Findings from this initial in vivo study support a role for multiple UGTs in the glucuronidation of tobacco-related compounds in vivo, in particular UGT2B10 and cotinine glucuronidation. Impact: Findings also provide insight into ethnic differences in glucuronidation activity, which could be contributing to ethnic disparities in the risk for smoking-related cancers. Cancer Epidemiol Biomarkers Prev; 24(1); 94–104. ©2014 AACR.Keywords
All Related Versions
This publication has 70 references indexed in Scilit:
- Glucuronidation of trans-3′-hydroxycotinine by UGT2B17 and UGT2B10Pharmacogenetics and Genomics, 2012
- Relationship Between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 Variation and Smoking Behaviors and Lung Cancer RiskJNCI: Journal of the National Cancer Institute, 2011
- Racial Differences in the Relationship Between Number of Cigarettes Smoked and Nicotine and Carcinogen ExposureNicotine & Tobacco Research, 2011
- Nicotinic Acetylcholine Receptor Region on Chromosome 15q25 and Lung Cancer Risk Among African Americans: A Case–Control StudyJNCI: Journal of the National Cancer Institute, 2010
- UGT2B10 Genotype Influences Nicotine Glucuronidation, Oxidation, and ConsumptionCancer Epidemiology, Biomarkers & Prevention, 2010
- Nicotine Metabolism in African Americans and European Americans: Variation in Glucuronidation by Ethnicity and UGT2B10 HaplotypeThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Subpicogram per Milliliter Determination of the Tobacco-Specific Carcinogen Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol in Human Urine Using Liquid Chromatography−Tandem Mass SpectrometryAnalytical Chemistry, 2008
- Adaptive Evolution of UGT2B17 Copy-Number VariationThe American Journal of Human Genetics, 2008
- Gene-environment interaction in tobacco-related cancersCarcinogenesis, 2008
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004